Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Watts Water Technologies Q3 diluted EPS jumps 77% to $4.34; Q3 net sales rise 19% to $728 million

Watts Water Technologies Q3 diluted EPS jumps 77% to $4.34; Q3 net sales rise 19% to $728 million

BitgetBitget2026/11/04 22:50
  • Watts Water Technologies' third-quarter 2026 diluted earnings per share jumped 77% year over year to $4.34.
  • Net sales rose 19% to $728 million, driven by higher volume primarily from data center growth and favorable pricing.
  • Operating margin widened 8 percentage points to 26.2%, primarily reflecting $39 million in tariff refunds.
  • Full-year 2026 guidance increased to net sales growth of 17%–18% and an operating margin of 21.6%–21.7%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Watts Water Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104302852) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss